In support of this hypothesis, Saddawi-Konefka et al. have recently demonstrated that the tumor response to α-CTLA-4 immunotherapy is dependent on the presence of cDC1 in the tumor-draining lymphatics23, while Darragh et al. correlated DLN IR to a general decrease in DCs in the DLNs26. The gene discussed is CTLA4; the disease is neoplasm.